CN114231563B - 用于视网膜及cns基因疗法的aav载体 - Google Patents
用于视网膜及cns基因疗法的aav载体 Download PDFInfo
- Publication number
- CN114231563B CN114231563B CN202111211678.0A CN202111211678A CN114231563B CN 114231563 B CN114231563 B CN 114231563B CN 202111211678 A CN202111211678 A CN 202111211678A CN 114231563 B CN114231563 B CN 114231563B
- Authority
- CN
- China
- Prior art keywords
- raav
- amino acid
- nucleic acid
- numbering
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002207 retinal effect Effects 0.000 title claims abstract description 41
- 238000001415 gene therapy Methods 0.000 title abstract description 10
- 239000013607 AAV vector Substances 0.000 title abstract description 6
- 238000006467 substitution reaction Methods 0.000 claims abstract description 612
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 451
- 239000002245 particle Substances 0.000 claims abstract description 378
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 238000010361 transduction Methods 0.000 claims abstract description 34
- 230000026683 transduction Effects 0.000 claims abstract description 34
- 208000022873 Ocular disease Diseases 0.000 claims abstract description 33
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 354
- 102000039446 nucleic acids Human genes 0.000 claims description 300
- 108020004707 nucleic acids Proteins 0.000 claims description 300
- 210000000234 capsid Anatomy 0.000 claims description 257
- 210000004027 cell Anatomy 0.000 claims description 178
- 108090000565 Capsid Proteins Proteins 0.000 claims description 131
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 131
- 230000001225 therapeutic effect Effects 0.000 claims description 118
- 210000003169 central nervous system Anatomy 0.000 claims description 117
- 239000013608 rAAV vector Substances 0.000 claims description 90
- 229920001184 polypeptide Polymers 0.000 claims description 87
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 87
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 73
- 201000010099 disease Diseases 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 43
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 29
- 208000002780 macular degeneration Diseases 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 19
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 18
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 18
- 210000001525 retina Anatomy 0.000 claims description 18
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 16
- 108091070501 miRNA Proteins 0.000 claims description 16
- 239000002679 microRNA Substances 0.000 claims description 16
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 15
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 13
- 208000023105 Huntington disease Diseases 0.000 claims description 13
- 208000018737 Parkinson disease Diseases 0.000 claims description 13
- 108020005544 Antisense RNA Proteins 0.000 claims description 12
- 108090000994 Catalytic RNA Proteins 0.000 claims description 12
- 102000053642 Catalytic RNA Human genes 0.000 claims description 12
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 12
- 201000007737 Retinal degeneration Diseases 0.000 claims description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 12
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 12
- 239000003184 complementary RNA Substances 0.000 claims description 12
- 210000001577 neostriatum Anatomy 0.000 claims description 12
- 108091092562 ribozyme Proteins 0.000 claims description 12
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 11
- 208000033379 Chorioretinopathy Diseases 0.000 claims description 11
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 11
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 11
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 11
- 208000014769 Usher Syndromes Diseases 0.000 claims description 11
- 230000004258 retinal degeneration Effects 0.000 claims description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 11
- 208000027073 Stargardt disease Diseases 0.000 claims description 10
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 10
- 239000003900 neurotrophic factor Substances 0.000 claims description 10
- 206010010356 Congenital anomaly Diseases 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 9
- 208000001344 Macular Edema Diseases 0.000 claims description 9
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims description 9
- 206010038848 Retinal detachment Diseases 0.000 claims description 9
- 201000008615 cone dystrophy Diseases 0.000 claims description 9
- 201000010206 cystoid macular edema Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 206010014801 endophthalmitis Diseases 0.000 claims description 9
- 230000004264 retinal detachment Effects 0.000 claims description 9
- 208000002691 Choroiditis Diseases 0.000 claims description 8
- 208000003971 Posterior uveitis Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 208000035719 Maculopathy Diseases 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 239000002924 silencing RNA Substances 0.000 claims 2
- 208000035545 CNGA3-related retinopathy Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 218
- 229920002971 Heparan sulfate Polymers 0.000 abstract description 126
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 abstract description 124
- 108090000054 Syndecan-2 Proteins 0.000 abstract description 124
- 230000001976 improved effect Effects 0.000 abstract description 20
- 239000013646 rAAV2 vector Substances 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 description 467
- 101710132601 Capsid protein Proteins 0.000 description 289
- 101710197658 Capsid protein VP1 Proteins 0.000 description 289
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 289
- 101710108545 Viral protein 1 Proteins 0.000 description 289
- 125000000539 amino acid group Chemical group 0.000 description 112
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 65
- 229940024606 amino acid Drugs 0.000 description 65
- 150000001413 amino acids Chemical class 0.000 description 65
- 108091028043 Nucleic acid sequence Proteins 0.000 description 54
- 239000004475 Arginine Substances 0.000 description 49
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 49
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 49
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 49
- 108091016585 CD44 antigen Proteins 0.000 description 42
- 210000004556 brain Anatomy 0.000 description 36
- 210000002569 neuron Anatomy 0.000 description 36
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 34
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 31
- 210000001508 eye Anatomy 0.000 description 31
- 230000002209 hydrophobic effect Effects 0.000 description 28
- 241000701022 Cytomegalovirus Species 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 24
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 22
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 22
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 22
- 239000013598 vector Substances 0.000 description 22
- 108091030071 RNAI Proteins 0.000 description 18
- 230000009368 gene silencing by RNA Effects 0.000 description 18
- 210000000449 purkinje cell Anatomy 0.000 description 18
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 17
- 210000001130 astrocyte Anatomy 0.000 description 17
- 210000004248 oligodendroglia Anatomy 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 230000002025 microglial effect Effects 0.000 description 16
- 210000004738 parenchymal cell Anatomy 0.000 description 16
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 14
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 14
- 241000714474 Rous sarcoma virus Species 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 12
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 12
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 12
- 208000003098 Ganglion Cysts Diseases 0.000 description 11
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 11
- 208000005400 Synovial Cyst Diseases 0.000 description 11
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 10
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 10
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 8
- 102100024081 Aryl-hydrocarbon-interacting protein-like 1 Human genes 0.000 description 8
- 108091012583 BCL2 Proteins 0.000 description 8
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 description 8
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 description 8
- 102000000405 Clarin Human genes 0.000 description 8
- 108050008883 Clarin Proteins 0.000 description 8
- 208000006992 Color Vision Defects Diseases 0.000 description 8
- 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 description 8
- 102100029140 Cyclic nucleotide-gated cation channel beta-3 Human genes 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 8
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 8
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 description 8
- 101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 8
- 208000015872 Gaucher disease Diseases 0.000 description 8
- 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 description 8
- 101000833576 Homo sapiens Aryl-hydrocarbon-interacting protein-like 1 Proteins 0.000 description 8
- 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 description 8
- 101000771083 Homo sapiens Cyclic nucleotide-gated cation channel beta-3 Proteins 0.000 description 8
- 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 description 8
- 101001044118 Homo sapiens Inosine-5'-monophosphate dehydrogenase 1 Proteins 0.000 description 8
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 8
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 8
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 8
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 8
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 8
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 8
- 101000742938 Homo sapiens Retinol dehydrogenase 12 Proteins 0.000 description 8
- 101000772173 Homo sapiens Tubby-related protein 1 Proteins 0.000 description 8
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 8
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 description 8
- 102100021602 Inosine-5'-monophosphate dehydrogenase 1 Human genes 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 102100033356 Lecithin retinol acyltransferase Human genes 0.000 description 8
- 241001630723 Lepophidium brevibarbe Species 0.000 description 8
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 8
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 8
- 102000010175 Opsin Human genes 0.000 description 8
- 108050001704 Opsin Proteins 0.000 description 8
- 101150046816 PRPH2 gene Proteins 0.000 description 8
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 8
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 8
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 description 8
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 8
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 8
- 102100038054 Retinol dehydrogenase 12 Human genes 0.000 description 8
- 108090000799 Rhodopsin kinases Proteins 0.000 description 8
- 102100029293 Tubby-related protein 1 Human genes 0.000 description 8
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 8
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 8
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 description 8
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 description 8
- 201000000761 achromatopsia Diseases 0.000 description 8
- -1 aspartyl Chemical group 0.000 description 8
- 208000030270 breast disease Diseases 0.000 description 8
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 description 8
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 8
- 201000007254 color blindness Diseases 0.000 description 8
- 210000002287 horizontal cell Anatomy 0.000 description 8
- 108010084957 lecithin-retinol acyltransferase Proteins 0.000 description 8
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 7
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 7
- 230000003959 neuroinflammation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000004382 visual function Effects 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 6
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 6
- 108010079505 Endostatins Proteins 0.000 description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 description 6
- 208000014060 Niemann-Pick disease Diseases 0.000 description 6
- 210000001638 cerebellum Anatomy 0.000 description 6
- 102000006734 Beta-Globulins Human genes 0.000 description 5
- 108010087504 Beta-Globulins Proteins 0.000 description 5
- 102100032487 Beta-mannosidase Human genes 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 5
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 5
- 108091006725 SLCO1C1 Proteins 0.000 description 5
- 102100027229 Solute carrier organic anion transporter family member 1C1 Human genes 0.000 description 5
- 108010017842 Telomerase Proteins 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 108010022394 Threonine synthase Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 102100022146 Arylsulfatase A Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000024720 Fabry Disease Diseases 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 102000036509 GTP Cyclohydrolase Human genes 0.000 description 4
- 108010023555 GTP Cyclohydrolase Proteins 0.000 description 4
- 102100028496 Galactocerebrosidase Human genes 0.000 description 4
- 108010042681 Galactosylceramidase Proteins 0.000 description 4
- 108010000540 Hexosaminidases Proteins 0.000 description 4
- 102000002268 Hexosaminidases Human genes 0.000 description 4
- 208000001089 Multiple system atrophy Diseases 0.000 description 4
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 4
- 210000000411 amacrine cell Anatomy 0.000 description 4
- 230000000151 anti-reflux effect Effects 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- 210000002330 subarachnoid space Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 description 3
- 101710117545 C protein Proteins 0.000 description 3
- 102000004627 Iduronidase Human genes 0.000 description 3
- 108010003381 Iduronidase Proteins 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 210000000576 arachnoid Anatomy 0.000 description 3
- 108010055059 beta-Mannosidase Proteins 0.000 description 3
- 210000001951 dura mater Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000003446 pia mater Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 108020005296 Acid Ceramidase Proteins 0.000 description 2
- 102000006772 Acid Ceramidase Human genes 0.000 description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 2
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 2
- 102100031491 Arylsulfatase B Human genes 0.000 description 2
- 102000009133 Arylsulfatases Human genes 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 101710195294 Beta-galactosidase 1 Proteins 0.000 description 2
- 102100026031 Beta-glucuronidase Human genes 0.000 description 2
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101100080277 Caenorhabditis elegans ncr-1 gene Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 2
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000037310 Gaucher disease type 2 Diseases 0.000 description 2
- 208000037311 Gaucher disease type 3 Diseases 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000004547 Glucosylceramidase Human genes 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 description 2
- 101001052076 Homo sapiens Maltase-glucoamylase Proteins 0.000 description 2
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 2
- 108010054377 Mannosidases Proteins 0.000 description 2
- 102000001696 Mannosidases Human genes 0.000 description 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 2
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 description 2
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 description 2
- 101710202061 N-acetyltransferase Proteins 0.000 description 2
- 101100459404 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) npc-1 gene Proteins 0.000 description 2
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 description 2
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010044965 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase Proteins 0.000 description 2
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 description 2
- 208000017441 X-linked retinoschisis Diseases 0.000 description 2
- WJFVEEAIYIOATH-KEWYIRBNSA-N [(2r,3r,4r,5r)-5-acetamido-3,4,6-trihydroxyoxan-2-yl]methyl hydrogen sulfate Chemical compound CC(=O)N[C@H]1C(O)O[C@H](COS(O)(=O)=O)[C@H](O)[C@@H]1O WJFVEEAIYIOATH-KEWYIRBNSA-N 0.000 description 2
- 108010070626 acid beta-galactosidase Proteins 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
- 108010012864 alpha-Mannosidase Proteins 0.000 description 2
- 102000019199 alpha-Mannosidase Human genes 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 201000008333 alpha-mannosidosis Diseases 0.000 description 2
- 239000000158 apoptosis inhibitor Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 201000006486 beta-mannosidosis Diseases 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 108010046910 brain-derived growth factor Proteins 0.000 description 2
- 210000004289 cerebral ventricle Anatomy 0.000 description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 2
- 229940045896 cnl8 Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000188 diaphragm Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 201000008049 fucosidosis Diseases 0.000 description 2
- 101150091511 glb-1 gene Proteins 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 201000004502 glycogen storage disease II Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 210000002418 meninge Anatomy 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 201000007714 retinoschisis Diseases 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 241000649044 Adeno-associated virus 9 Species 0.000 description 1
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 102100032948 Aspartoacylase Human genes 0.000 description 1
- 108700023155 Aspartoacylases Proteins 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- 208000009796 Gangliosidoses Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 description 1
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 101150116978 RPE65 gene Proteins 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 108700001567 Type I Schindler Disease Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111211678.0A CN114231563B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988131P | 2014-05-02 | 2014-05-02 | |
| US61/988,131 | 2014-05-02 | ||
| US201562114575P | 2015-02-10 | 2015-02-10 | |
| US62/114,575 | 2015-02-10 | ||
| CN202111211678.0A CN114231563B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
| PCT/US2015/028966 WO2015168666A2 (en) | 2014-05-02 | 2015-05-02 | Aav vectors for retinal and cns gene therapy |
| CN201580035996.2A CN106661591B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580035996.2A Division CN106661591B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114231563A CN114231563A (zh) | 2022-03-25 |
| CN114231563B true CN114231563B (zh) | 2024-08-16 |
Family
ID=53189202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580035996.2A Active CN106661591B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
| CN202111211678.0A Active CN114231563B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580035996.2A Active CN106661591B (zh) | 2014-05-02 | 2015-05-02 | 用于视网膜及cns基因疗法的aav载体 |
Country Status (32)
Families Citing this family (179)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| RS67077B1 (sr) | 2009-05-02 | 2025-08-29 | Genzyme Corp | Genska terapija za neurodegenerativne poremećaje |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP3514232A1 (en) | 2010-04-23 | 2019-07-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| WO2011133874A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Multicistronic expression constructs |
| JP2013533847A (ja) | 2010-04-23 | 2013-08-29 | ユニバーシティ オブ マサチューセッツ | コレステロール関連障害のａａｖベースの治療 |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| WO2012145624A2 (en) | 2011-04-21 | 2012-10-26 | University Of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| RS66184B1 (sr) | 2011-04-22 | 2024-12-31 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
| RU2692251C2 (ru) | 2013-05-15 | 2019-06-24 | Риджентс Оф Зэ Юниверсити Оф Миннесота | Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему |
| ES2897508T3 (es) | 2013-05-31 | 2022-03-01 | Univ California | Variantes de virus adenoasociados y métodos de uso de las mismas |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| WO2015127128A2 (en) | 2014-02-19 | 2015-08-27 | University Of Massachusetts | Recombinant aavs having useful transcytosis properties |
| KR102288849B1 (ko) | 2014-03-17 | 2021-08-12 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| DK3119797T3 (da) | 2014-03-18 | 2021-03-15 | Univ Massachusetts | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose |
| US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
| EP4600255A3 (en) | 2014-05-02 | 2025-10-22 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
| MX383227B (es) * | 2014-05-14 | 2025-03-13 | UNIV AUTòNOMA DE BARCELONA | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico. |
| US10689653B2 (en) | 2014-06-03 | 2020-06-23 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
| RU2020140209A (ru) | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| US10450563B2 (en) | 2015-02-10 | 2019-10-22 | Genzyme Corporation | Variant RNAi |
| AU2016219398A1 (en) | 2015-02-10 | 2017-09-28 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
| EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
| KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| EP3719134B1 (en) | 2015-03-11 | 2023-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Rp2 vectors for treating x-linked retinitis pigmentosa |
| EP3277819B1 (en) | 2015-03-24 | 2021-03-03 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| RS61907B1 (sr) | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| US20180104289A1 (en) | 2015-04-08 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Viral gene therapy as treatment for cholesterol storage disease or disorder |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| WO2016172008A1 (en) | 2015-04-24 | 2016-10-27 | University Of Massachusetts | Modified aav constructions and uses thereof |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| EP3831842A1 (en) | 2015-09-28 | 2021-06-09 | The University of North Carolina at Chapel Hill | Methods and compositions for antibody-evading virus vectors |
| CA3002982A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
| US11426469B2 (en) | 2015-10-22 | 2022-08-30 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| EP3368054A4 (en) | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV) |
| AU2016366549B2 (en) | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| MX2018007330A (es) * | 2015-12-15 | 2019-03-14 | Genzyme Corp | Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii. |
| US11826433B2 (en) | 2016-02-02 | 2023-11-28 | University Of Massachusetts | Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system |
| CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| US20190071681A1 (en) * | 2016-02-26 | 2019-03-07 | University Of Florida Research Foundation, Incorporated | Aav heparin mutants that display significantly improved eye and brain transduction |
| WO2017176929A1 (en) | 2016-04-05 | 2017-10-12 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| CN107287238B (zh) * | 2016-04-11 | 2020-10-16 | 厦门继景生物技术有限责任公司 | 一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物 |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| GB201608046D0 (en) | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| AU2017268382B2 (en) * | 2016-05-18 | 2023-09-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| EP3481958A4 (en) * | 2016-07-08 | 2019-12-25 | The Trustees of The University of Pennsylvania | METHOD AND COMPOSITIONS FOR TREATING DISTURBANCES AND DISEASES WITH RDH12 |
| WO2018011572A1 (en) * | 2016-07-12 | 2018-01-18 | The University Of Manchester | Gene therapy |
| JP7071332B2 (ja) | 2016-07-29 | 2022-05-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 変異カプシドを有するアデノ随伴ウイルスビリオン及びその使用方法 |
| BR112019002904A2 (pt) * | 2016-08-16 | 2019-06-25 | The University Of North Carolina At Chapel Hill | métodos e composições para transferência gênica direcionada |
| IL264872B2 (en) * | 2016-08-18 | 2025-02-01 | Univ California | CRISPR-CAS genome engineering using a modular AAV delivery system |
| WO2018035457A1 (en) * | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus |
| KR102759317B1 (ko) | 2016-08-19 | 2025-01-31 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물 |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| KR20190057110A (ko) | 2016-09-28 | 2019-05-27 | 코바, 인크. | 치료적 mots-c 관련 펩타이드 |
| US11078238B2 (en) | 2016-09-29 | 2021-08-03 | University Of Florida Research Foundation, Incorporated | AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| MX2019006614A (es) | 2016-12-07 | 2019-10-15 | Univ Florida | Adnc del antagonista del receptor de interleucina-1. |
| WO2018145009A1 (en) * | 2017-02-06 | 2018-08-09 | University Of Tennessee Research Foundation | Dna-zyme based methods & compositions for treating huntington's disease |
| US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| US10898585B2 (en) | 2017-04-14 | 2021-01-26 | Ptc Therapeutics .Inc. | Gene therapy for AADC deficiency |
| WO2018200419A1 (en) * | 2017-04-23 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Viral vectors comprising engineered aav capsids and compositions containing the same |
| WO2018204803A1 (en) * | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| JP7327803B2 (ja) | 2017-05-09 | 2023-08-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症（ａｌｓ）を処置する方法 |
| JP7330899B2 (ja) | 2017-05-10 | 2023-08-22 | マサチューセッツ アイ アンド イヤー インファーマリー | ウイルスのアセンブリ活性化タンパク質（ａａｐ）依存性を改変する方法および組成物 |
| CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
| US20200121746A1 (en) | 2017-06-30 | 2020-04-23 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| EP3662060A2 (en) * | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US11680249B2 (en) | 2017-08-28 | 2023-06-20 | The Regents Of The University Of California | Adeno-associated virus capsid variants and methods of use thereof |
| US20200377887A1 (en) * | 2017-09-22 | 2020-12-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| EP3684932A1 (en) | 2017-09-22 | 2020-07-29 | Genzyme Corporation | Variant rnai |
| CN111448321A (zh) | 2017-09-22 | 2020-07-24 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
| CN111601884A (zh) * | 2017-10-16 | 2020-08-28 | 维格内罗有限责任公司 | Aav载体 |
| WO2019077159A1 (en) * | 2017-10-20 | 2019-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| AU2018368431B2 (en) | 2017-11-14 | 2024-03-21 | Arcellx, Inc. | Multifunctional immune cell therapies |
| CR20200210A (es) * | 2017-11-15 | 2020-09-23 | Friedrich Miescher Institute For Biomedical Res | Promotor especìfico de las cèlulas del epitelio pigmentario retinal en primates |
| AU2018367606B2 (en) * | 2017-11-15 | 2024-08-29 | The Regents Of The University Of Michigan | Viral vectors comprising RDH12 coding regions and methods of treating retinal dystrophies |
| US20190153440A1 (en) | 2017-11-21 | 2019-05-23 | Casebia Therapeutics Llp | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| CN108085316B (zh) * | 2017-12-25 | 2021-02-09 | 中国人民解放军第四军医大学 | 一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法 |
| US20210017509A1 (en) * | 2018-03-23 | 2021-01-21 | The Trustees Of Columbia University In The City Of New York | Gene Editing for Autosomal Dominant Diseases |
| WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| EP3773743A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| BR112020021903A2 (pt) | 2018-04-27 | 2021-03-02 | Rocket Pharmaceuticals, Ltd. | terapia genética para degeneração do snc |
| MX2020012077A (es) | 2018-05-15 | 2021-03-09 | Voyager Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad de parkinson. |
| TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒（ａａｖ）之組成物和方法 |
| EP3813845A4 (en) | 2018-05-15 | 2022-10-26 | President And Fellows Of Harvard College | Viral vectors exhibiting improved gene delivery properties |
| WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
| JP7563694B2 (ja) * | 2018-06-01 | 2024-10-08 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 優性網膜色素変性症の処置のための組成物および方法 |
| EP3802829A4 (en) | 2018-06-08 | 2022-10-19 | University of Massachusetts | ANTISENSE OLIGONUCLEOTIDES TO RESTORE DYSFERLIN PROTEIN EXPRESSION IN CELLS FROM PATIENTS WITH DYSFERLINOPATHY |
| PH12021550254A1 (en) | 2018-08-03 | 2023-02-06 | Genzyme Corp | Variant rnai against alpha-synuclein |
| CN109022487A (zh) * | 2018-08-15 | 2018-12-18 | 上海市第人民医院 | 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物 |
| KR20210084459A (ko) | 2018-09-26 | 2021-07-07 | 캘리포니아 인스티튜트 오브 테크놀로지 | 표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물 |
| SG11202103151RA (en) | 2018-09-28 | 2021-04-29 | Voyager Therapeutics Inc | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020077091A1 (en) * | 2018-10-10 | 2020-04-16 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| EP3863662A1 (en) * | 2018-10-12 | 2021-08-18 | Genzyme Corporation | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| WO2020099956A1 (en) * | 2018-11-13 | 2020-05-22 | Indian Institute Of Technology Kanpur | A process for producing a plurality of sumoylation target-site modified aav vector and product thereof |
| CA3120923A1 (en) * | 2018-11-26 | 2020-06-04 | Universitat Autonoma De Barcelona | Fibroblast growth factor 21 (fgf21) gene therapy |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| US20220089670A1 (en) * | 2018-12-28 | 2022-03-24 | University Of Rochester | Gene Therapy for BEST1 Dominant Mutations |
| WO2020142653A1 (en) * | 2019-01-04 | 2020-07-09 | Ultragenyx Pharmaceutical Inc. | Gene therapy constructs for treating wilson disease |
| CN113631225A (zh) | 2019-01-18 | 2021-11-09 | 沃雅戈治疗公司 | 用于生产aav颗粒的方法和系统 |
| CA3125294A1 (en) * | 2019-01-23 | 2020-07-30 | University Of Florida Research Foundation, Incorporated | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
| CN113518784A (zh) | 2019-01-28 | 2021-10-19 | 科巴公司 | 治疗性肽 |
| FI3850089T3 (fi) | 2019-02-04 | 2024-02-14 | Freeline Therapeutics Ltd | Polynukleotidejä |
| US20200297869A1 (en) * | 2019-03-04 | 2020-09-24 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
| JP7549360B2 (ja) * | 2019-03-04 | 2024-09-11 | デューク ユニバーシティ | 網膜症の診断および処置のための組成物および方法 |
| WO2020182722A1 (en) * | 2019-03-08 | 2020-09-17 | Universite Paris-Saclay | Improved therapeutic method for rare ocular diseases by gene replacement |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| WO2020210713A1 (en) * | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| US12491263B2 (en) | 2019-05-13 | 2025-12-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Polymer-based implant for retinal therapy and methods of making and using the same |
| KR20220009427A (ko) * | 2019-05-17 | 2022-01-24 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 글리코시드 가수분해효소를 사용하는 망막 세포에 대한 유전자 치료 벡터의 개선된 전달 |
| MX2021015076A (es) * | 2019-06-10 | 2022-06-02 | Homology Medicines Inc | Composiciones de virus adeno-asociados para transferencia del gen de la enzima lisosomal arilsulfatasa-a (arsa) y metodos de uso de las mismas. |
| WO2020264438A2 (en) | 2019-06-27 | 2020-12-30 | University Of Florida Research Foundation, Incorporated | Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid |
| US11446084B2 (en) | 2019-07-12 | 2022-09-20 | Neuralink Corp. | Laser drilling of pia mater |
| HRP20241647T1 (hr) * | 2019-07-15 | 2025-02-14 | Meiragtx Uk Ii Limited | Modificirani proteini aav kapsida za liječenje artritične bolesti |
| CN110295151A (zh) * | 2019-07-17 | 2019-10-01 | 博鑫仪器(天津)有限公司 | 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法 |
| WO2021041324A2 (en) * | 2019-08-23 | 2021-03-04 | Duke University | Compositions and methods for the treatment of pathological pain and itch |
| WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| EP4025258A4 (en) * | 2019-09-03 | 2023-09-06 | University of Cincinnati | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
| JP2022551487A (ja) * | 2019-10-10 | 2022-12-09 | ソリッド・バイオサイエンシーズ・インコーポレーテッド | 改変されたａａｖカプシドおよびその使用 |
| TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療ｃ型尼曼—匹克病之腺相關病毒載體 |
| CA3155154A1 (en) * | 2019-10-23 | 2021-04-29 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| US20220396808A1 (en) * | 2019-11-08 | 2022-12-15 | President And Fellows Of Harvard College | Viral capsid polypeptides |
| CN113025618B (zh) * | 2019-12-24 | 2024-02-06 | 朗信启昇(苏州)生物制药有限公司 | 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用 |
| AU2021213786A1 (en) | 2020-01-29 | 2022-09-22 | Genzyme Corporation | Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof |
| KR20220150906A (ko) * | 2020-02-07 | 2022-11-11 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 신경변성의 발병 지연 또는 치료를 위한 대사체의 재프로그래밍 |
| JP2023515795A (ja) * | 2020-02-18 | 2023-04-14 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Ａａｖカプシド－プロモーター相互作用および細胞選択的遺伝子発現 |
| EP4110913A4 (en) * | 2020-02-28 | 2024-07-24 | University of Massachusetts | OLIGONUCLEOTIDES FOR PRNP MODULATION |
| CN115379834A (zh) * | 2020-03-11 | 2022-11-22 | 马萨诸塞眼科耳科诊所 | 用于nmnat1相关视网膜变性的基因疗法 |
| US20230138766A1 (en) * | 2020-03-31 | 2023-05-04 | University Of Massachusetts | Aav capsids variants and uses thereof |
| WO2021209521A1 (en) * | 2020-04-14 | 2021-10-21 | Genethon | Vectors for the treatment of acid ceramidase deficiency |
| MX2022012752A (es) | 2020-04-15 | 2023-01-16 | Voyager Therapeutics Inc | Compuestos de union a tau. |
| US20230203102A1 (en) | 2020-05-13 | 2023-06-29 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| JP2023529503A (ja) * | 2020-06-13 | 2023-07-10 | オクロジェネクス インコーポレイテッド | 網膜症のためのａａｖ媒介性遺伝子導入 |
| CN113952472A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| WO2022017630A1 (en) | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
| CA3190309A1 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| BR112023001336A2 (pt) | 2020-08-05 | 2023-02-14 | Spacecraft Seven Llc | Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina) |
| CN116194154A (zh) | 2020-08-07 | 2023-05-30 | 太空飞船七有限责任公司 | 使用aav载体的plakophilin-2(pkp2)基因疗法 |
| TW202227632A (zh) | 2020-08-19 | 2022-07-16 | 美商史崔德生物公司 | 用於治療雷特症候群之腺相關病毒載體 |
| US20230330267A1 (en) * | 2020-09-04 | 2023-10-19 | Ohio State Innovation Foundation | Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain |
| WO2022087238A1 (en) * | 2020-10-21 | 2022-04-28 | Wisconsin Alumni Research Foundation | Anti-apoptotic vector and method of using the same |
| US20220160825A1 (en) * | 2020-11-25 | 2022-05-26 | The Penn State Research Foundation | Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion |
| WO2022178410A1 (en) * | 2021-02-22 | 2022-08-25 | The Regents Of The University Of Colorado, A Body Corporate | Viral vector-based gene therapy for ocular conditions |
| CN115044614B (zh) * | 2021-03-09 | 2023-10-20 | 上海目镜生物医药科技有限公司 | 一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用 |
| EP4329824A4 (en) * | 2021-04-26 | 2025-08-20 | Grace Science Llc | COMPOSITIONS AND METHODS FOR TREATING NGYL1 DEFICIENCY |
| EP4399314A4 (en) * | 2021-09-06 | 2025-09-10 | Huidagene Therapeutics Singapore Pte Ltd | TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65 |
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023093905A1 (zh) | 2021-11-29 | 2023-06-01 | 上海瑞宏迪医药有限公司 | Aadc、gdnf多核苷酸及其用于治疗帕金森病 |
| WO2023155918A1 (zh) | 2022-02-21 | 2023-08-24 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| EP4499154A1 (en) * | 2022-03-25 | 2025-02-05 | REGENXBIO Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| CN119487188A (zh) * | 2022-04-19 | 2025-02-18 | 上海天泽云泰生物医药有限公司 | 用于治疗神经退行性障碍的重组aav载体 |
| US20250171778A1 (en) * | 2022-04-25 | 2025-05-29 | Myrtelle Inc. | Treatments of Disorders of Myelin |
| AU2023260469A1 (en) | 2022-04-25 | 2024-11-14 | Cell Cure Neurosciences, Ltd. | Methods and compositions for treating vision loss |
| US20250353883A1 (en) | 2022-05-06 | 2025-11-20 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
| WO2023240220A1 (en) * | 2022-06-09 | 2023-12-14 | The University Of North Carolina At Chapel Hill | Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024008950A1 (en) | 2022-07-08 | 2024-01-11 | Ospedale San Raffaele S.R.L. | Transgene cassettes |
| EP4303226A1 (en) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgene cassettes and epigenetic silencers for the treatment of disorders |
| AU2023306319A1 (en) * | 2022-07-12 | 2025-02-13 | The Research Institute At Nationwide Children's Hospital | Adeno-associated virus gene therapy products and methods |
| AU2023427408A1 (en) | 2023-02-02 | 2025-09-04 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024218311A1 (fr) | 2023-04-21 | 2024-10-24 | Pulsesight Therapeutics | Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine |
| GB202306952D0 (en) * | 2023-05-11 | 2023-06-28 | Neurochase Innovations Ltd | Method |
| WO2025128817A1 (en) | 2023-12-15 | 2025-06-19 | Genzyme Corporation | Artificial micrornas targeting tau |
| WO2025160452A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Methods for fus-based delivery of viral particles to the brain |
| WO2025160434A1 (en) | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting huntington's disease |
| WO2025160429A1 (en) | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting snca |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1486567A1 (en) * | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| CN103561774A (zh) * | 2011-04-22 | 2014-02-05 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| US5735815A (en) | 1993-07-26 | 1998-04-07 | Sentinel Medical, Inc. | Method of using fluid jet surgical cutting tool |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| NZ500427A (en) | 1997-04-21 | 2002-12-20 | Univ Florida | The use of ribozyme treatment for retinal diseases |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| ES2326893T3 (es) | 1998-05-27 | 2009-10-21 | Genzyme Corporation | Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion. |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
| US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| DK1496944T3 (da) | 2002-05-01 | 2008-12-01 | Univ Florida | Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner |
| AU2004226961B2 (en) * | 2002-05-01 | 2009-06-11 | University Of Florida Research Foundation, Inc. | VP2-modified rAAV vector compositions and uses therefor |
| PT1625210E (pt) | 2003-05-21 | 2011-03-15 | Genzyme Corp | Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios |
| PL3235827T3 (pl) * | 2003-06-19 | 2021-07-05 | Genzyme Corporation | Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowania |
| CA2581714C (en) | 2004-10-05 | 2017-09-12 | Avigen, Inc. | Stepped cannula |
| EP2357010B1 (en) * | 2005-04-07 | 2013-06-12 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| WO2007024841A2 (en) | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
| US7867484B2 (en) * | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| EP2023949A4 (en) | 2006-04-26 | 2009-08-26 | Univ California | COMPOSITIONS AND METHODS FOR CONVECTION-REINFORCED RELEASE OF NEUROTHERAPEUTICS WITH HIGH MOLECULAR WEIGHT |
| US20090317417A1 (en) | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
| WO2008144585A1 (en) | 2007-05-17 | 2008-11-27 | Medgenesis Therapeutix Inc. | Convection-enhanced delivery catheter with removable stiffening member and method for using same |
| US20100081707A1 (en) | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| BRPI1007155A2 (pt) | 2009-01-29 | 2017-05-30 | Univ Of California San Francisco | métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata |
| ES2634118T3 (es) | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
| CN102803478B (zh) | 2009-06-16 | 2016-04-27 | 建新公司 | 用于纯化重组aav载体的改进方法 |
| EP3514232A1 (en) | 2010-04-23 | 2019-07-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| WO2015012501A1 (ko) | 2013-07-25 | 2015-01-29 | 주식회사 스마트캐스터 | 비공기압 바퀴 |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| EP4600255A3 (en) | 2014-05-02 | 2025-10-22 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
-
2015
- 2015-05-02 EP EP25153064.8A patent/EP4600255A3/en active Pending
- 2015-05-02 JP JP2016564301A patent/JP6741591B2/ja active Active
- 2015-05-02 KR KR1020167033392A patent/KR20160147974A/ko not_active Ceased
- 2015-05-02 IL IL248102A patent/IL248102B/en unknown
- 2015-05-02 HR HRP20211024TT patent/HRP20211024T4/hr unknown
- 2015-05-02 KR KR1020257031397A patent/KR20250141850A/ko active Pending
- 2015-05-02 SG SG11201607991WA patent/SG11201607991WA/en unknown
- 2015-05-02 ES ES15723386T patent/ES2879636T5/es active Active
- 2015-05-02 CN CN201580035996.2A patent/CN106661591B/zh active Active
- 2015-05-02 SG SG10201912977RA patent/SG10201912977RA/en unknown
- 2015-05-02 PT PT157233867T patent/PT3137497T/pt unknown
- 2015-05-02 US US15/308,335 patent/US10982228B2/en active Active
- 2015-05-02 EP EP21159585.5A patent/EP3913061A1/en active Pending
- 2015-05-02 IL IL292951A patent/IL292951B2/en unknown
- 2015-05-02 PE PE2016002164A patent/PE20170260A1/es unknown
- 2015-05-02 EA EA201692206A patent/EA034355B1/ru not_active IP Right Cessation
- 2015-05-02 LT LTEP15723386.7T patent/LT3137497T/lt unknown
- 2015-05-02 SI SI201531642T patent/SI3137497T2/sl unknown
- 2015-05-02 RS RS20210849A patent/RS62078B2/sr unknown
- 2015-05-02 CA CA2946593A patent/CA2946593A1/en active Pending
- 2015-05-02 HU HUE15723386A patent/HUE054768T2/hu unknown
- 2015-05-02 CR CR20160555A patent/CR20160555A/es unknown
- 2015-05-02 DK DK15723386.7T patent/DK3137497T4/da active
- 2015-05-02 WO PCT/US2015/028966 patent/WO2015168666A2/en not_active Ceased
- 2015-05-02 EP EP15723386.7A patent/EP3137497B2/en active Active
- 2015-05-02 MY MYPI2016703542A patent/MY188987A/en unknown
- 2015-05-02 AU AU2015252797A patent/AU2015252797C1/en active Active
- 2015-05-02 MX MX2016014220A patent/MX2016014220A/es unknown
- 2015-05-02 FI FIEP15723386.7T patent/FI3137497T4/fi active
- 2015-05-02 PL PL15723386.7T patent/PL3137497T5/pl unknown
- 2015-05-02 CN CN202111211678.0A patent/CN114231563B/zh active Active
- 2015-05-02 SG SG10201809739QA patent/SG10201809739QA/en unknown
- 2015-05-02 KR KR1020247006248A patent/KR102863726B1/ko active Active
- 2015-05-04 UY UY0001036106A patent/UY36106A/es not_active Application Discontinuation
- 2015-05-04 TW TW104114126A patent/TWI686476B/zh active
-
2016
- 2016-09-30 ZA ZA2016/06763A patent/ZA201606763B/en unknown
- 2016-10-13 PH PH12016502046A patent/PH12016502046A1/en unknown
- 2016-10-19 DO DO2016000280A patent/DOP2016000280A/es unknown
- 2016-10-24 GT GT201600227A patent/GT201600227A/es unknown
- 2016-10-25 CL CL2016002713A patent/CL2016002713A1/es unknown
- 2016-10-28 MX MX2022012490A patent/MX2022012490A/es unknown
-
2018
- 2018-01-19 CL CL2018000170A patent/CL2018000170A1/es unknown
-
2020
- 2020-06-24 JP JP2020108310A patent/JP7174011B2/ja active Active
-
2021
- 2021-01-15 AU AU2021200242A patent/AU2021200242B9/en active Active
- 2021-03-05 US US17/194,009 patent/US12241078B2/en active Active
-
2022
- 2022-11-02 JP JP2022175918A patent/JP7682142B2/ja active Active
-
2023
- 2023-12-20 AU AU2023285817A patent/AU2023285817A1/en active Pending
-
2024
- 2024-12-27 JP JP2024231483A patent/JP2025065116A/ja active Pending
-
2025
- 2025-01-30 US US19/041,853 patent/US20250320522A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1486567A1 (en) * | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| CN103561774A (zh) * | 2011-04-22 | 2014-02-05 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7682142B2 (ja) | 網膜およびｃｎｓ遺伝子治療用ａａｖベクター | |
| HK40071052A (en) | Aav vectors for retinal and cns gene therapy | |
| HK40071052B (zh) | 用於视网膜及cns基因疗法的aav载体 | |
| HK40064049A (en) | Aav vectors for retinal and cns gene therapy | |
| HK1234076B (en) | Aav vectors for retinal and cns gene therapy | |
| BR112016025263B1 (pt) | Usos: de uma partícula de vírus adenoassociado recombinante (raav), de um kit, e de uma composição compreendendo uma partícula de vírus adenoassociado recombinante (raav) | |
| BR122020026753B1 (pt) | Uso de uma partícula de vírus adenoassociado recombinante (raav) na fabricação de um medicamento para distribuir um ácido nucleico heterólogo ao olho de um indivíduo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40071052 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |